Tomomi Kashiwada

656 total citations
25 papers, 200 citations indexed

About

Tomomi Kashiwada is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Tomomi Kashiwada has authored 25 papers receiving a total of 200 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 16 papers in Pulmonary and Respiratory Medicine and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Tomomi Kashiwada's work include Gastric Cancer Management and Outcomes (14 papers), Colorectal Cancer Treatments and Studies (10 papers) and HER2/EGFR in Cancer Research (8 papers). Tomomi Kashiwada is often cited by papers focused on Gastric Cancer Management and Outcomes (14 papers), Colorectal Cancer Treatments and Studies (10 papers) and HER2/EGFR in Cancer Research (8 papers). Tomomi Kashiwada collaborates with scholars based in Japan. Tomomi Kashiwada's co-authors include Akitaka Makiyama, Hironaga Satake, Eiji Oki, Mototsugu Shimokawa, Hiroshi Saeki, Yoshihiko Maehara, Masaaki Iwatsuki, Yukiya Narita, Hideto Sonoda and Yoshiko Matsuda and has published in prestigious journals such as Journal of Clinical Oncology, Annals of Oncology and European Journal of Cancer.

In The Last Decade

Tomomi Kashiwada

22 papers receiving 198 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Tomomi Kashiwada Japan 7 150 139 41 40 37 25 200
Minori Koshiji Rosales United States 6 135 0.9× 75 0.5× 23 0.6× 36 0.9× 31 0.8× 11 158
Светлана Проценко Russia 5 138 0.9× 102 0.7× 30 0.7× 17 0.4× 26 0.7× 11 184
Nanfeng Fan China 9 112 0.7× 152 1.1× 53 1.3× 17 0.4× 74 2.0× 22 238
Yohei Kubota Japan 5 95 0.6× 98 0.7× 25 0.6× 9 0.2× 52 1.4× 12 202
Evgeny Gotovkin Russia 4 113 0.8× 150 1.1× 46 1.1× 10 0.3× 75 2.0× 4 200
Kanwal Pratap Singh Raghav United States 5 163 1.1× 117 0.8× 89 2.2× 14 0.3× 61 1.6× 8 245
Tomokazu Hisayuki Japan 7 140 0.9× 94 0.7× 23 0.6× 16 0.4× 76 2.1× 20 186
Yuriy Ostapenko Ukraine 3 131 0.9× 149 1.1× 62 1.5× 19 0.5× 73 2.0× 6 227
Ina Valeria Zurlo Italy 6 105 0.7× 89 0.6× 12 0.3× 15 0.4× 42 1.1× 24 191

Countries citing papers authored by Tomomi Kashiwada

Since Specialization
Citations

This map shows the geographic impact of Tomomi Kashiwada's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Tomomi Kashiwada with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Tomomi Kashiwada more than expected).

Fields of papers citing papers by Tomomi Kashiwada

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Tomomi Kashiwada. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Tomomi Kashiwada. The network helps show where Tomomi Kashiwada may publish in the future.

Co-authorship network of co-authors of Tomomi Kashiwada

This figure shows the co-authorship network connecting the top 25 collaborators of Tomomi Kashiwada. A scholar is included among the top collaborators of Tomomi Kashiwada based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Tomomi Kashiwada. Tomomi Kashiwada is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kawakami, Takeshi, Tetsutaro Hamano, Toshiki Masuishi, et al.. (2024). Prospective observational study investigating the impact of treatment sequence using regorafenib and FTD/TPI for metastatic colorectal cancer on overall survival (OSERO study).. Journal of Clinical Oncology. 42(3_suppl). 103–103.
2.
Hu, Qingjiang, Eiji Oki, Teppei Yamada, et al.. (2023). Genomic characterization between HER2‐positive and negative gastric cancer patients in a prospective trial. Cancer Medicine. 12(15). 16649–16660. 7 indexed citations
3.
Hosaka, Hisashi, Ryohei Kawabata, Naoki Nagata, et al.. (2023). Phase II trial evaluating the efficacy of capeOX in elderly patients with advanced gastric cancer using geriatric assessment (TCOG GI-1601).. Journal of Clinical Oncology. 41(4_suppl). 348–348. 1 indexed citations
4.
Narita, Yukiya, Shuichi Hironaka, Hisato Kawakami, et al.. (2023). 149P A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS. Annals of Oncology. 34. S1532–S1533. 1 indexed citations
5.
Kashiwada, Tomomi, Katsunori Shinozaki, Hirofumi Kawanaka, et al.. (2020). Safety and efficacy of S-1 plus oxaliplatin 130 mg/m2 combination therapy in patients with previously untreated HER2-negative unresectable, advanced, or recurrent gastric/gastroesophageal junction cancer: a phase II trial (KSCC1501A). International Journal of Clinical Oncology. 26(2). 345–354. 1 indexed citations
6.
Oki, Eiji, Akitaka Makiyama, Yuji Miyamoto, et al.. (2020). Trifluridine/tipiracil plus bevacizumab as a first‐line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial. Cancer Medicine. 10(2). 454–461. 17 indexed citations
7.
Nakajima, Hiromichi, Shota Fukuoka, Toshikazu Moriwaki, et al.. (2020). Clinical impact of primary tumor location in patients with metastatic colorectal cancer (mCRC) treated with regorafenib or trifluridine/tipiracil as later-line.. Journal of Clinical Oncology. 38(4_suppl). 105–105. 1 indexed citations
8.
Kashiwada, Tomomi, et al.. (2019). Nab-paclitaxel plus ramucirumab combination therapy as second-line with advanced gastric cancer:Retrospective study. Annals of Oncology. 30. vi140–vi140. 1 indexed citations
9.
Yuki, Satoshi, Katsunori Shinozaki, Tomomi Kashiwada, et al.. (2019). Multicenter phase II study of SOX plus trastuzumab for patients with HER2+ metastatic or recurrent gastric cancer: KSCC/HGCSG/CCOG/PerSeUS 1501B. Cancer Chemotherapy and Pharmacology. 85(1). 217–223. 19 indexed citations
10.
Masuishi, Toshiki, Toshikazu Moriwaki, Shota Fukuoka, et al.. (2019). Predictive factors for early mortality after initiation of regorafenib or trifluridine/tipiracil in refractory metastatic colorectal cancer.. Journal of Clinical Oncology. 37(15_suppl). 3560–3560.
11.
Makiyama, Akitaka, Eiji Oki, Yuji Miyamoto, et al.. (2019). Bevacizumab plus trifluridine/tipiracil in elderly patients with previously untreated metastatic colorectal cancer (KSCC 1602): A single-arm, phase II study. Annals of Oncology. 30. v234–v235. 1 indexed citations
12.
13.
14.
Saeki, Hiroshi, Eiji Oki, Tomomi Kashiwada, et al.. (2018). Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604). European Journal of Cancer. 105. 41–49. 77 indexed citations
15.
Matsusaka, Satoshi, Tomomi Kashiwada, Koichi Suzuki, et al.. (2017). Detection of KRAS Mutations in Plasma DNA Using a fully Automated Rapid Detection System in Colorectal Cancer Patients. Pathology & Oncology Research. 23(4). 737–744. 2 indexed citations
16.
Shinozaki, Katsunori, Satoshi Yuki, Tomomi Kashiwada, et al.. (2017). A phase II study (KSCC/HGCSG/CCOG/PerSeUS1501B) of trastuzumab plus S-1 and oxaliplatin for HER2-positive advanced gastric cancer.. Journal of Clinical Oncology. 35(15_suppl). 4059–4059. 1 indexed citations
17.
Makiyama, Akitaka, Mototsugu Shimokawa, Tomomi Kashiwada, et al.. (2017). Trastuzumab beyond first progression in cases of HER2-positive advanced gastric or gastro-esophageal junction cancer: Initial results from KSCC1105, a trastuzumab observational cohort study.. Journal of Clinical Oncology. 35(4_suppl). 93–93. 4 indexed citations
18.
19.
Denda, Tadamichi, Mitsuro Kanda, Yoshitaka Morita, et al.. (2016). Pharmacokinetic dose adjustment of 5-FU in modified FOLFOX7 plus bevacizumab for metastatic colorectal cancer in Japanese patients: a-JUST phase II clinical trial. Cancer Chemotherapy and Pharmacology. 78(6). 1253–1261. 14 indexed citations
20.
Kashiwada, Tomomi, Kazutoshi Komiya, Takahiko Nakazono, et al.. (2015). A case with cancer of unknown primary diagnosed pathologically retroperitoneal squamous cell carcinoma. Annals of Oncology. 26. vii112–vii112. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Minori Koshiji Rosales Breakdown of academic impact, for papers by Светлана Проценко Breakdown of academic impact, for papers by Nanfeng Fan Breakdown of academic impact, for papers by Yohei Kubota Breakdown of academic impact, for papers by Evgeny Gotovkin Breakdown of academic impact, for papers by Kanwal Pratap Singh Raghav Breakdown of academic impact, for papers by Tomokazu Hisayuki Breakdown of academic impact, for papers by Yuriy Ostapenko Breakdown of academic impact, for papers by Ina Valeria Zurlo
Rankless by CCL
2026